Test your knowledge
Module 4: Addressing patient concerns
Introduction
There is a shared responsibility for improving health and the provision of care between patients, the public and the NHS. Since the Wanless Report, ‘Securing our future health: taking a long-term view’ published in 2002, there remains a gap between personalised care and the experience of patients.1,2 Patients are often not supported with making healthy choices and there are rising concerns about the consequences for population health.2 Lack of sleep causes enormous detriment to the patient, the workforce and the healthcare system.3
As the landscape of chronic insomnia evolves, this module aims to equip GPs with practical strategies to support patients grappling with persistent sleep disturbances.
Learning objectives
By completing this module, you will increase your awareness and understanding of:
- the patient's journey from initial symptoms to seeking treatment
- the benefits and challenges of current treatment options
- discussing QUVIVIQ™ with patients: how to take it and how to address patient concerns
Multiple-choice questions to test your current knowledge
These questions will help you assess your current knowledge of this topic before you begin to work on the module. Your answers will be marked but will not count towards your final score. You will be asked the same questions again at the end of the module and will be able to download a learning certificate for your records upon completion.
Ready for the next step?
Delayed management of chronic insomnia patients
CBTi: cognitive behavioural therapy for insomnia
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.4
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- Wanless, D. Securing our future health: taking a long-term view. Final report, April 2002. Available at: yearofcare.co.uk. Accessed August 2025
- Ham C, Charles A, Wellings D. Shared responsibility for health: the cultural change we need, November 2018. Available at: kingsfund.org.uk. Accessed August 2025
- Lim D C, Najafi A et al. The need to promote sleep health in public health agendas across the globe. Lancet Public Health 2023;8(10):e820-e826
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00656 | Date of preparation: September 2025
